08:00 , Feb 2, 2012 |  BC Innovations  |  Targets & Mechanisms

Closing the gap on liver toxicity

U.S. researchers have identified a small molecule gap junction inhibitor that protects mice from drug-induced liver toxicity.1 The team has founded Heprotech Inc. to further characterize and optimize the inhibitor. Gap junctions are multiprotein channel structures...
07:00 , May 5, 2003 |  BC Week In Review  |  Company News

Zealand Pharma, Wyeth deal

WYE will co-develop ZP123 from Zealand to treat arrhythmias and other cardiovascular diseases. The ZP123 peptide acts on gap junctions, which help maintain normal heart rhythm. The partners will collaborate on preclinical studies, and WYE...
07:00 , May 1, 2003 |  BC Extra  |  Company News

Zealand, Wyeth cardiovascular deal

WYE will co-develop ZP123 from Zealand (Glostrup, Denmark) to treat arrhythmias and other cardiovascular diseases. ZP123 peptide acts on gap junctions, which help maintain normal heart rhythm. The partners will collaborate on preclinical studies, and...